A suspected delayed hemolytic transfusion reaction mediated by anti-Joa by Jajosky, Ryan P. et al.
IMMUNOHEMATOLOGY, Volume 33, Number 2, 2017 73
A suspected delayed hemolytic transfusion 
reaction mediated by anti-Joa
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Case RepoRt
A 32-year-old African-American woman with a history of sickle 
cell disease presented for surgical evaluation of left total hip 
arthroplasty due to avascular necrosis of the femoral head. In 
anticipation of a complex orthopedic procedure, pre-surgical 
blood work was ordered. The patient’s Fenwal blood sample 
typed as group O, D+. Although the patient had a history of 
anti-Fya, the antibody identification was inconclusive, so the 
workup was sent to a reference laboratory. The patient was last 
transfused with red blood cells (RBCs) 2 years earlier, but had 
no history of transfusion reactions. Due to surgery, the patient’s 
hemoglobin (Hb) decreased from 10.2 g/dL (preoperative) 
to 8.6 g/dL (postoperative). One unit of weakly crossmatch-
incompatible Fy(a–), C–, E–, K–, and sickle cell hemoglobin 
S (HbS)-negative RBCs was transfused without incident, and 
the patient was discharged. Several days later, the reference lab 
reported two new specificities, anti-Joa and anti-Jkb. Fortunately, 
the transfused RBC unit was Jk(b–). Therefore, the crossmatch 
incompatibility was attributed to anti-Joa, which targets a high-
prevalence antigen found in 100 percent of most populations. 
Two weeks after discharge, the patient returned in sickle vaso-
occlusive pain crisis. The patient was clinically stable, but her Hb 
was 6.7 g/dL.  One unit of Fy(a–), Jk(b–), C–, E–, K–, HbS– RBCs, 
which was weakly crossmatch-incompatible, was transfused. The 
following day, her Hb was unchanged, lactic acid dehydrogenase 
increased from 951 to 2464 U/L, potassium increased from 3.7 
to 4.6 mEq/L, creatinine increased from 0.60 to 0.98 mg/dL, and 
the patient developed a 38.4°C fever. These findings are consistent 
with a delayed hemolytic transfusion reaction (DHTR), mediated 
by anti-Joa, occurring 2 weeks after the first RBC transfusion. 
Further care could not be provided because the patient left the 
hospital against medical advice. The purpose of this case study 
is to report findings consistent with a DHTR attributed to anti-
Joa, an antibody with relatively unknown clinical significance. 
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The Dombrock blood group system consists of antithetical 
antigens, Doa and Dob, and the high-prevalence antigens, Gya, 
Hy, Joa, DOYA, DOMR, and DOLG.1,2 The DO gene is located 
on chromosome 12p12.3, contains 3 exons, and encodes a 
protein comprised of 314 amino acids.1–3 The Do glycoprotein 
is an ADP-ribosyltransferase (CD297) that is linked via 
glycosylphosphatidylinositol (GPI) to the red blood cell (RBC) 
membrane.1 The glycoprotein is absent in the Donull phenotype, 
known as Gy(a–), which is rarely found in persons of white, 
black, Japanese, and Chinese populations.2 The Gy(a–) 
phenotype is not associated with pathology, although the 
RBCs of patients with paroxysmal nocturnal hemoglobinuria 
Type III lack the Do glycoprotein.3 Dombrock antibodies are 
typically IgG-restricted, weakly reactive, and do not activate 
complement.2 Anti-Doa and -Dob can cause acute4 and delayed 
hemolytic transfusion reactions, but not hemolytic disease of 
the fetus and newborn (HDFN).2 Rare literature reports about 
anti-Joa exist, linking this specificity to delayed hemolytic 
transfusion reactions (DHTRs).1,5
The Jo(a–) phenotype is caused by the 350C>T nucleotide 
substitution, causing an amino acid change from Thr to Ile at 
amino acid position 117.1 To date, only rare African-American 
individuals have been identified with the Jo(a–) phenotype,2 
although more than 99 percent of these individuals express 
Joa.2 RBC genotyping of ethnic groups in West, Central, and 
East Africa revealed the allele frequencies for DO*01.–05, the 
Jo(a–) phenotype, to be as high as 15 percent.6 Joa and Hy (ISBT 
[International Society of Blood Transfusion] allele DO*02.–04) 
show a phenotypical relationship. RBCs that are Jo(a–) have 
weak reactivity with anti-Doa, no or weak reactivity with anti-
Dob, reactivity with anti-Gya, and weak reactivity with anti-
Hy.2 RBCs that are Hy– often type as Jo(a–), and the proximity 
of Hy (amino acid 108) and Joa (amino acid 117) likely explains 
this phenomenon.3 Nevertheless, some Hy– RBCs have been 
shown to express weak Joa.7 Patients who are Jo(a–) may be 
either DO*01.–05/DO*01.–05 or DO*02.–04/DO*01.–05.2 
Because of past confusion of anti-Hy as anti-Joa, it is best to 
use reagent RBCs tested by DNA analysis to confirm anti-Joa 
specificity.2 
Case Report
A 32-year-old African-American woman with a history of 
sickle cell disease (SCD) was seen for left total hip arthroplasty 
due to avascular necrosis of the femoral head. Blood type and 
an antibody detection test were ordered on the day of surgery. 
The patient’s RBCs typed as group O, D+. Previous records 
showed a known anti-Fya, acquired from past transfusion. The 
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antibody identification panel showed weak to 1+ panreactivity 
with Fy(a–) cells. The patient was last transfused with RBCs 2 
years earlier, was not on a chronic transfusion regimen, and had 
no history of transfusion reactions. The autocontrol and direct 
antiglobulin test (DAT) were negative, so a novel alloantibody 
was suspected. Because the antibody identification was 
inconclusive, a pre-transfusion blood sample was sent to 
a reference laboratory for antibody identification and RBC 
genotyping. Later that day, the surgery was performed with an 
estimated blood loss of 450 mL, reducing the hemoglobin (Hb) 
from 10.2 to 8.6 g/dL (reference range 14.0–18.0 g/dL). One 
unit of RBCs was ordered emergently. One unit of Fy(a–), C–, 
E–, K–, HbS– RBCs was selected, but was weakly crossmatch 
incompatible. The unit was released with a risk form with 
orders to “transfuse with caution.” The transfusion proceeded 
without incident, and the patient was discharged in stable 
condition.
Several days after discharge, the reference lab reported 
their findings. Anti-Fya and new anti-Joa and anti-Jkb were 
identified. The RBC unit transfused during the hospitalization 
was known to be Jk(b–). Thus, the crossmatch incompatibility 
was attributed to anti-Joa, which targets a high-prevalence 
antigen found in 100 percent of most populations. The anti-Joa 
was reactive by indirect antiglobulin test (IAT), polyethylene 
glycol (PEG)-IAT, and ficin-IAT. Genotyping predicted the 
patient’s RBCs to be Fy(a–b–), Do(a+b+), Jo(a–), and Hy+. 
In addition, the patient was homozygous for the Duffy null 
promoter FY*02N.01 and for RHCE*01.01, which is associated 
with altered expression of e and the presence of a variant e 
allele.8  
The patient was non-compliant with her prophylactic 
medications, and 2 weeks after discharge, the patient was 
admitted to the hospital because of a sickle-related vaso-
occlusive pain crisis. Although the patient was clinically 
stable, her Hb was 6.7 g/dL, so 1 unit of RBCs was emergently 
ordered. One unit of Fy(a–), Jk(b–), C–, E–, K–, HbS– RBCs, 
which was weakly crossmatch incompatible, was transfused. 
The crossmatch incompatibility was attributed to anti-
Joa. Several hours after completion of the transfusion, the 
patient’s temperature peaked at 38.4°C, which was 37.1°C 
pre-transfusion. On the following day, the Hb was unchanged. 
Lactic acid dehydrogenase (LDH) increased from 951 to 2464 
U/L (reference range 120–246 U/L), potassium (K+) increased 
from 3.7 to 4.6 mEq/L (reference range 3.5–5.5 mEq/L), and 
creatinine (Cr) increased from 0.60 to 0.98 mg/dL (reference 
range 0.6–1.60 mg/dL). The clinical team suspected a 
hemolytic transfusion reaction. The patient was informed 
about the suspected transfusion reaction; however, the patient 
was upset and left the hospital against medical advice.
Discussion
This case report serves to contribute to the rare literature 
implicating anti-Joa in DHTRs.1,5 Joa is a high-prevalence 
antigen in the Dombrock blood group system, which is found 
in 100 percent of most populations. Only African-American 
individuals have been identified as being Jo(a–); although the 
antigen is still present in greater than 99 percent of individuals 
in this population. Because finding Jo(a–) units can be nearly 
impossible in an emergent setting, it is important to understand 
the clinical significance of anti-Joa.
The patient presented in this case report demonstrated 
findings consistent with that known about the Jo(a–) 
phenotype. The patient was African American, and her RBCs 
typed as Do(a+b+) and Hy+. On two separate occasions, the 
patient was transfused with 1 unit of RBCs, each of which 
was weakly crossmatch incompatible, attributed to anti-
Joa. Transfusion of the first RBC unit was not immediately 
associated with symptoms of a transfusion reaction. However, 
2 weeks later, the patient returned with an Hb of 6.7 g/dL. 
The patient received a second RBC unit that was weakly 
crossmatch incompatible, also attributable to anti-Joa. On the 
following day, the Hb remained unchanged, LDH spiked, K+ 
and Cr increased, and the patient experienced a new-onset 
fever. These findings are consistent with a DHTR, occurring 2 
weeks after transfusion of the first RBC unit. DHTRs typically 
occur days to weeks after transfusion and are mediated by non-
brisk extravascular hemolysis. Patients may be asymptomatic, 
but with unexplained anemia. Fortunately, most DHTRs 
have a benign course and require only supportive care, with 
monitoring of the hematocrit.  
In retrospect, the transfusion reaction was potentially 
avoidable. Both RBC transfusions could be categorized as 
overtransfusion because the patient was clinically stable 
before being transfused. On the day after the first transfusion 
of 1 RBC unit, the patient was discharged because she was 
clinically stable, just as she had been prior to transfusion. In 
addition, the second transfusion of 1 RBC unit could have been 
avoided. In general, patients with SCD who are clinically stable 
with a high reticulocyte count do not need RBC transfusions.9 
This patient was in sickle pain crisis in stable condition with 
a 6.7 g/dL Hb and reticulocyte count of 11.9%. From the 
perspective of judicious transfusion medicine practice, the 
risk of a hemolytic transfusion reaction from a crossmatch-
incompatible RBC unit outweighed the potential benefits.  
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Other transfusion management options could have been 
considered in a non-urgent/non-emergent setting. Rare donor 
registries, such as the American Rare Donor Program (ARDP), 
are an effective tool for finding antigen-negative RBC units. 
Although they are even more rare than Jo(a–) units, Gy(a–) 
units would also be compatible because Gy(a–) represents 
the Donull phenotype. Family members of the patient could 
have been tested to identify those who were ABO compatible, 
Fy(a–), Jk(b–), C–, E–, K–, HbS–, and possibly Jo(a–). 
Another option to ensure the safety of transfusion therapy 
is the monocyte monolayer assay (MMA).10 This could have 
been used to predict the clinical significance of the anti-Joa. 
An MMA with a monocyte index of more than 5 percent would 
have supported avoidance of transfusion in this case. Lastly, 
hemoglobin-based oxygen carriers (HBOCs) may become 
an alternative therapy for patients requiring RBCs that are 
difficult to obtain. Some patients may be able to receive HBOCs 
through clinical trials.11
Conclusions
This case report presents findings that are consistent 
with a DHTR due to anti-Joa, a rare antibody of relatively 
unknown clinical significance. The transfusion medicine 
service should be aware that anti-Joa has been implicated in 
DHTRs. The risks and benefits of transfusing an incompatible 
unit should be assessed for each patient. Because Joa is a 
high-prevalence antigen, securing Jo(a–) blood can be nearly 
impossible in an urgent/emergent setting. In a non-emergent 
setting, accessing the ARDP, testing likely Jo(a–) blood donors, 
such as persons of African-American ethnicity and family 
members, and the use of hemoglobin-based oxygen carriers 
are possible options to avoid hemolytic reactions. Fortunately, 
several weeks after the transfusion reaction, the patient 
returned to our hospital as an outpatient in stable condition.  
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